Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer
Conditions
Interventions
F-18 16 alpha-fluoroestradiol
fludeoxyglucose F 18
+4 more
Locations
1
United States
University of Washington Medical Center
Seattle, Washington, United States
Start Date
September 1, 2008
Primary Completion Date
August 1, 2011
Completion Date
September 1, 2014
Last Updated
February 19, 2020
NCT01953588
NCT03962647
NCT03719495
NCT02235051
NCT00676663
NCT02269670
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions